Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in Delaware: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 840 | 18% |
| 2020 | 1 | 643 | 20% |
| 2021 | 4 |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Delaware; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 57 | 12,034+3.1%/yr | +3.1%/yr | 68.10.6× | 37% | 18,400 in 2030+7.3%/yr |
| Bone graft & orthobiologics |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in Delaware · Every state · Compare with Florida
| 2024 |
| 1,763 |
| 35% |
| 2025 est. | ≈ 2,080 | – |
| 2026 est. | ≈ 2,340 | – |
| 690 |
| 25% |
| 2022 | 5 | 800 | 29% |
| 2023 | 5 | 1,455 | 32% |
| 2024 | 5 | 1,763 | 35% |
| 2025 from claims | – | 2,083 1,911–2,204 | 35% |
| 2026 forecast | – | 2,337 2,056–2,697 | 35% |
| 2027 forecast | – | 2,612 2,233–3,113 | 36% |
| 2028 forecast | – | 2,920 2,437–3,576 | 36% |
| 2029 forecast | – | 3,264 2,666–4,093 | 37% |
| 2030 forecast | – | 3,648 2,923–4,675 | 37% |
In 2025, 8% hospital outpatient, 1% surgery center, 91% office. The share outside the hospital has moved +58 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center | Office |
|---|---|---|---|
| 2026 · ~2,300 | ~140 | ~23 | ~2,200 |
| 2027 · ~2,600 | ~130 | ~26 | ~2,500 |
| 2028 · ~2,900 | ~140 | ~28 | ~2,800 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 5% (8% in 2025), office about 94% (91% in 2025).
| 48,756+22%/yr |
| +22%/yr |
| 13.2 |
| 77% |
| 79,300 in 2030+8.4%/yr |
| Georgia | 65 | 14,399+9.3%/yr | +9.3%/yr | 9.7 | 74% | 20,000 in 2030+5.6%/yr |
| Oklahoma | 48 | 11,719+21%/yr | +21%/yr | 16.6 | 72% | 19,200 in 2030+8.6%/yr |
| Tennessee | 38 | 9,735+16%/yr | +16%/yr | 8.3 | 69% | 15,600 in 2030+8.1%/yr |
| Virginia | 47 | 9,709+14%/yr | +14%/yr | 6.5 | 70% | 21,900 in 2030+14%/yr |
| South Carolina | 44 | 8,777+14%/yr | +14%/yr | 8.4 | 72% | 16,300 in 2030+11%/yr |
| Mississippi | 39 | 8,487+28%/yr | +28%/yr | 15.3 | 68% | 14,900 in 2030+9.8%/yr |
| Alabama | 31 | 7,567+19%/yr | +19%/yr | 9.4 | 82% | 11,800 in 2030+7.7%/yr |
| North Carolina | 35 | 7,475+4.4%/yr | +4.4%/yr | 4.4 | 66% | 10,800 in 2030+6.4%/yr |
| Kentucky | 24 | 7,085+18%/yr | +18%/yr | 9.2 | 65% | 11,400 in 2030+8.3%/yr |
| Louisiana | 33 | 6,694+10%/yr | +10%/yr | 9.4 | 82% | 12,700 in 2030+11%/yr |
| Maryland | 25 | 5,850+12%/yr | +12%/yr | 5.3 | 70% | 12,200 in 2030+13%/yr |
| Arkansas | 17 | 4,095+20%/yr | +20%/yr | 7.1 | 73% | 6,940 in 2030+9.2%/yr |
| West Virginia | 12 | 3,280+21%/yr | +21%/yr | 9.3 | 82% | 4,240 in 2030+4.4%/yr |
| District of Columbia | 4 | 1,007+12%/yr | +12%/yr | 11.6 | 83% | 2,200 in 2030+14%/yr |
| 7 |
| 334−2.8%/yr |
| −2.8%/yr |
| 1.92.8× |
| 11% |
| 340 in 2030+0.5%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Convatec leads with 64% of company spending on these surgeons in 2025, +23 pts on 2024.
In 2025, 17 companies reported engagement with Delaware’s surgeons worth $189K in consulting, speaking, meals and travel tied to these products, about $38K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.